(0.10%) 5 522.50 points
(0.14%) 39 898 points
(0.21%) 19 793 points
(-0.02%) $81.61
(0.53%) $2.83
(-0.25%) $2 338.50
(0.22%) $29.59
(0.42%) $1 006.00
(0.03%) $0.932
(-0.05%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
2.33% € 86.61
@ €86.70
Wydano: 24 birž. 2024 @ 19:18
Zwrot: -0.10%
Poprzedni sygnał: birž. 21 - 21:10
Poprzedni sygnał:
Zwrot: 2.93 %
Live Chart Being Loaded With Signals
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 1.12M |
Średni wolumen | 712 112 |
Kapitalizacja rynkowa | 20.59B |
EPS | €-1.310 ( Q1 | 2024-05-06 ) |
Następna data zysków | ( €-1.980 ) 2024-08-05 |
Last Dividend | €2.26 ( 2022-06-02 ) |
Next Dividend | €0 ( N/A ) |
P/E |
169.82 (Sector) 42.63 (Industry) 24.32 |
ATR14 | €1.890 (2.18%) |
Wolumen Korelacja
BioNTech SE Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
OZEM | 1 |
HPCO | 0.949 |
KRSOX | 0.919 |
OPTX | 0.916 |
ATXS | 0.91 |
UXIN | 0.908 |
NUVO | 0.906 |
NYXH | 0.904 |
LDTC | 0.904 |
CRGX | 0.897 |
10 Najbardziej negatywne korelacje | |
---|---|
INDH | -0.895 |
PPRUX | -0.876 |
ADSEW | -0.875 |
SFBC | -0.874 |
BOTT | -0.869 |
PSTR | -0.867 |
ELTX | -0.867 |
CCSB | -0.865 |
VCEL | -0.863 |
KRUS | -0.862 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BioNTech SE Korelacja - Waluta/Towar
BioNTech SE Finanse
Annual | 2023 |
Przychody: | €3.82B |
Zysk brutto: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2023 |
Przychody: | €3.82B |
Zysk brutto: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2022 |
Przychody: | €17.31B |
Zysk brutto: | €12.78B (73.82 %) |
EPS: | €38.08 |
FY | 2021 |
Przychody: | €18.98B |
Zysk brutto: | €15.12B (79.66 %) |
EPS: | €40.63 |
Financial Reports:
No articles found.
BioNTech SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
First Dividend | €2.26 | 2022-06-02 |
Last Dividend | €2.26 | 2022-06-02 |
Next Dividend | €0 | N/A |
Payout Date | 2022-06-17 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | €2.26 | -- |
Avg. Dividend % Per Year | 0.16% | -- |
Score | 1.82 | -- |
Div. Sustainability Score | 7.79 | |
Div.Growth Potential Score | 3.87 | |
Div. Directional Score | 5.83 | -- |
Year | Amount | Yield |
---|---|---|
2022 | €2.26 | 0.98% |
2023 | €0 | 0.00% |
2024 | €0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
02 Jun 2022 | €2.26 | 27 Apr 2022 | 03 Jun 2022 | 17 Jun 2022 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0414 | 1.500 | 9.17 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00508 | 1.200 | 9.83 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00565 | 1.500 | -1.048 | -1.572 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 11.38 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 10.95 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 5.59 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0106 | -1.500 | 9.82 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -17.52 | 1.000 | -7.60 | -7.60 | [3 - 30] |
operatingCashFlowPerShareTTM | 23.83 | 2.00 | 2.06 | 4.11 | [0 - 30] |
freeCashFlowPerShareTTM | 20.55 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0118 | -1.500 | 9.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.475 | 1.000 | 5.42 | 5.42 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.173 | 1.000 | -5.45 | -5.45 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 24.26 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.123 | 0.800 | -2.52 | -2.01 | [0.5 - 2] |
Total Score | 7.79 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 168.49 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00565 | 2.50 | -0.674 | -1.572 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 20.55 | 2.00 | 3.15 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 23.83 | 2.00 | 2.06 | 4.11 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 6.36 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 2.10 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 3.87 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej